1Almenoff J, Tonning JM, Lawrence Gould A, et al. Perspectives on the use of data mining in Pharmacovigilance [ J ]. Drug Safety,2005, 28 ( 11 ) : 981-1007.
2Bate A, Lindquist M, Edwards IR, et al. WHO' s International Drug Monitoring- The Formative Years 1968-1974 [ J ]. Drug Safety,2010,33 (7) : el -e23.
3http : //www. who-umc, org.
4A Bayesian neural network method for adverse drug reaction signal generation [ J ]. European Journal of Clinical Pharmacology, 1998,54 : 315-321.
5Bate A, Lindquist M, Orre R, et al. Automated classification of signals as group effects or drag specific on the WHO database[ C ]. 8th Annual Meeting European Society of Pharmacovigilance,Verona: Elsevier,2000.
6Edwards IR, Lindquist M. Understanding andcommunication of key concepts in therapeutics [ A ]. In: Moments of Truth, Communicating Drug Safety[ M]. Verona: Elsevier,2000.
7Lindquist M. The WHO Programme for International Drug Monitoring: the present and future[A]. In: Mitchard M. Electronic Communication Technologies [ M ]. 1998. 527-549.
8邵明立,曹立亚,张承绪.欧盟药物警戒体系与法规[M].北京:中国医药科技出版社,2006.
9EMEA. Guideline on the use of statistical signal detection methods in the Eudravigilance DataAnalysisSystem [ EB! OL]. http://www, emea. europa, eu/pdfs/human/phvwp/ 10646406enfin. pdf , 2008-06-28/2009-01-01.
8Du Wei, Eeh VT, Caverly M, et al. Incidence and Costs of Adverse Drug Reactions in a Tertiary Care Pediatric Intensive Care Unit [ J ]. J clin Pharm, 2013,53(5) :567 -573.
9Tobin JR. Pediatric drug labeling: still an unfinished need. Anesth Analg [ J ]. 2012,115 (5) :987 - 988.
